Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Colin A. Martz(Duke University), Kris C. Wood(Duke University), Kathleen Ottina(Howard Hughes Medical Institute), Katherine R. Singleton(Duke University), Keith T. Flaherty(Cancer Research Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Suzanne E. Wardell(Duke University), Lawrence N. Kwong(The University of Texas MD Anderson Cancer Center), Jeffrey C. Rathmell(University of Chicago), Michael Tetzlaff(The University of Texas MD Anderson Cancer Center), Jeff S. Jasper(Duke University), Donald P. McDonnell(Duke University), Holly M. Alley(Duke University), Peter Winter(Duke University), Zachary A. Cooper(AstraZeneca (Singapore)), Pei-Ling Chen(The University of Texas MD Anderson Cancer Center), Grace R. Anderson(Duke University), Timothy C. Wang(Columbia University), Ashley Peraza-Penton(Duke University), David M. Sabatini(Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry)
Cited by 199
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k